Volume 147, Issue 6, Pages 1327-1337.e3 (December 2014) Probiotic VSL#3 Reduces Liver Disease Severity and Hospitalization in Patients With Cirrhosis: A Randomized, Controlled Trial Radha K. Dhiman, Baldev Rana, Swastik Agrawal, Ashish Garg, Madhu Chopra, Kiran K. Thumburu, Amit Khattri, Samir Malhotra, Ajay Duseja, Yogesh K. Chawla Gastroenterology Volume 147, Issue 6, Pages 1327-1337.e3 (December 2014) DOI: 10.1053/j.gastro.2014.08.031 Copyright © 2014 AGA Institute Terms and Conditions
Figure 1 CONSORT diagram. ITT, intent to treat. Gastroenterology 2014 147, 1327-1337.e3DOI: (10.1053/j.gastro.2014.08.031) Copyright © 2014 AGA Institute Terms and Conditions
Figure 2 Hazard of breakthrough episode of hepatic encephalopathy in the probiotic and placebo groups. Gastroenterology 2014 147, 1327-1337.e3DOI: (10.1053/j.gastro.2014.08.031) Copyright © 2014 AGA Institute Terms and Conditions
Figure 3 Hazard of hospitalization in the probiotic and placebo groups. Gastroenterology 2014 147, 1327-1337.e3DOI: (10.1053/j.gastro.2014.08.031) Copyright © 2014 AGA Institute Terms and Conditions
Supplementary Figure 1 Hazard of death in the probiotic and placebo groups. Gastroenterology 2014 147, 1327-1337.e3DOI: (10.1053/j.gastro.2014.08.031) Copyright © 2014 AGA Institute Terms and Conditions
Supplementary Figure 2 CTP scores at baseline, and at 12 and 24 weeks in the probiotic and placebo groups. Gastroenterology 2014 147, 1327-1337.e3DOI: (10.1053/j.gastro.2014.08.031) Copyright © 2014 AGA Institute Terms and Conditions
Supplementary Figure 3 MELD scores at baseline, and at 12 and 24 weeks in the probiotic and placebo groups. Gastroenterology 2014 147, 1327-1337.e3DOI: (10.1053/j.gastro.2014.08.031) Copyright © 2014 AGA Institute Terms and Conditions